Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01964326 · ClinicalTrials.gov registry record · Phase 3
Actual Use Trial of Atorvastatin Calcium 10 mg
A Phase 3 study of Hypercholesterolemia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,311
- Enrollment target
- 20
- Study locations
NCT01964326: Completed Phase 3 study of Hypercholesterolemia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
NCT01964326 is a Phase 3 study of Hypercholesterolemia that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 1,311 participants, above the 796-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (65% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01964326, a Phase 3 study of Hypercholesterolemia, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,311 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this actual use study is to simulate the over the counter use of atorvastatin calcium 10 mg.
Primary Outcome
Percentage of participants whose behavior was either correct or acceptable were considered to be compliant. The behavior was considered correct if participants had their LDL-C checked between Weeks 4 and 12. The behavior was considered acceptable if participants had their LDL-C checked between Weeks 2 and 3 (before Week 4) or between Weeks 13 (after Week 12) and 26 or if participants were instructed by a physician that an LDL-C test was not needed.
Conditions Studied
Interventions
- DRUG Atorvastatin calcium 10 mg
Study Locations (20)
Minnesota
- Kemper Drug - Elk River
- Goodrich Pharmacy - Fridley
- Northfield Pharmacy - Northfield
- Cub Pharmacy - Rosemount
- Goodrich Pharmacy - Saint Francis
Alabama
- Robert's Discount Pharmacy - Hoover
- Pharmacy at the Pig - McCalla
- Pinson Discount Drugs - Pinson
Florida
- Garden Drug - Fort Lauderdale
- Pill Box Pharmacy and Medical Supply - Pembroke Pines
- Summerfield Pharmacy - Riverview
Arizona
- Community Clinical Pharmacy - Mesa
- Melrose Pharmacy - Phoenix
California
- Bi-Rite Quality Pharmacies - La Habra
- Parkview Compounding Pharmacy - Rancho Cucamonga
Georgia
- Sutton Family Pharmacy - Dalton
- Wynn's Pharmacy Inc. - Griffin
Missouri
- Albers' Medical Pharmacy - Kansas City
- Countryside Pharmacy - Savannah
Maryland
- Catonsville Pharmacy - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,311 participants |
| Start Date | 2013-10 |
| Est. Completion | 2014-12 |
| Phase | Phase 3 |
What the finished NCT01964326 record still lists
NCT01964326 is an interventional study that assigns participants to a tested intervention. Its 1,311 participants enrollment target places it among the larger protocols in the corpus, above the 796-participant average among 62 other Hypercholesterolemia trials with a reported enrollment target (65% higher).
The record links to 1 condition, with Hypercholesterolemia appearing as the primary indexed condition, and to 1 intervention - of which Atorvastatin calcium 10 mg is the first listed.
NCT01964326 names 20 study sites across 8 states, led by Minnesota, Alabama, Florida.
Frequently Asked Questions
What is clinical trial NCT01964326 about?
NCT01964326 is a clinical study titled "Actual Use Trial of Atorvastatin Calcium 10 mg". The purpose of this actual use study is to simulate the over the counter use of atorvastatin calcium 10 mg.
What is the current status of trial NCT01964326?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,311 participants. The study started on 2013-10. Estimated completion is 2014-12.
What conditions does trial NCT01964326 study?
This clinical trial studies the following conditions: Hypercholesterolemia.
What interventions are being tested in trial NCT01964326?
The interventions under investigation include: Atorvastatin calcium 10 mg (DRUG).
Who is sponsoring clinical trial NCT01964326?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01964326 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hypercholesterolemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01964326's enrollment target sits among peer trials
1,311 8th of 62 higher than 55 of 62 other Hypercholesterolemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hypercholesterolemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension
ACTIVE NOT RECRUITING · Phase 3
-
Effect of a Decision Aid About Statin Use in Patients With Type 2 Diabetes Mellitus
COMPLETED · Phase 3
-
Evaluation of Evolocumab (AMG 145) Efficacy in Diabetic Adults With Hypercholesterolemia/Mixed Dyslipidemia
COMPLETED · Phase 3
-
Action to Control Cardiovascular Risk in Diabetes (ACCORD)
COMPLETED · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Enlicitide Decanoate (MK-0616, Oral PCSK9 Inhibitor) Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With Hypercholesterolemia (MK-0616-018) CORALreef AddOn
COMPLETED · Phase 3
-
GLobal Assessment of Plaque reGression With a PCSK9 antibOdy as Measured by intraVascular Ultrasound
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06556433 · 1,312 participants · NA
Family-Based Financial Incentives Intervention for Smoking Cessation
- NCT06136624 · 1,310 participants · Phase 3
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
- NCT05176483 · 1,314 participants · Phase 1
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
- NCT06136650 · 1,314 participants · Phase 3
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia